Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Secondary Hyperparathyroidism - Overview
Secondary Hyperparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Secondary Hyperparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
Amgen Inc
EA Pharma Co Ltd
Lupin Ltd
Mitsubishi Tabe Pharma Corp
OPKO Health Inc
Secondary Hyperparathyroidism - Drug Profiles
AJT-240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcifediol ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cicalcet - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTA-091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dendocrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etelcalcetide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
evocalcet - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LNP-1892 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary Hyperparathyroidism - Dormant Projects
Secondary Hyperparathyroidism - Discontinued Products
Secondary Hyperparathyroidism - Product Development Milestones
Featured News & Press Releases
Sep 04, 2018: OPKO initiates RAYALDEE phase 2 trial in dialysis patients
Jul 16, 2018: OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Cada
May 22, 2018: Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintence Dialysis in Japan
Mar 23, 2018: Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintence Dialysis in Japan
Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology
Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD
Jun 05, 2017: OPKO Health Provides Commercial Update for RAYALDEE
Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintence Dialysis Patients in Japan
Feb 15, 2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis
Feb 07, 2017: OPKO Health Promotes Thomas Nusbickel to Rel Division Chief Commercial Officer
Feb 07, 2017: FDA Approves Amgen’s Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan
Jan 10, 2017: Study Results Published in the Jourl of the American Medical Association Show Amgen’s Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
Dec 19, 2016: ONO Receives Manufacturing and Marketing Approval in Japan for PARSABIV, a Calcimimetic Agent, for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis
Nov 18, 2016: ONO Announces Results from Phase 1/2 and Long- term Clinical Studies of Etelcalcetide Hydrochloride (ONO -5163) in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan at ASN Kidney Week 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Secondary Hyperparathyroidism, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Secondary Hyperparathyroidism, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Secondary Hyperparathyroidism - Pipeline by Amgen Inc, H2 2019
Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, H2 2019
Secondary Hyperparathyroidism - Pipeline by Lupin Ltd, H2 2019
Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, H2 2019
Secondary Hyperparathyroidism - Dormant Projects, H2 2019
Secondary Hyperparathyroidism - Discontinued Products, H2 2019